Fig 1.

Immune B cells mediate protection of JE-ADVAX vaccine against JEV challenge. Eight-week-old β₂m^−/− donor mice were immunized with two doses of 0.5 μg of ccJE plus 1 mg Advax delivered 2 weeks apart, B cells and CD4⁺ T cells were purified at 1 month after completion of the vaccination schedule, and 5 × 10⁶ cells were adoptively transferred into 8-week-old β₂m^−/− recipient mice. A control group of β₂m^−/− mice received naïve total splenocytes. At 1 day posttransfer, mice were challenged s.c. with 10³ PFU of JEV. Mice were monitored twice daily for morbidity and mortality over a 21-day observation period. Asterisks denote statistical significance (***, P < 0.001).